Investment Rating - The industry rating is "Outperform the Market" [53] Core Insights - The report highlights the successful launch of China's largest sustainable aviation fuel (SAF) facility by Honeywell and Zhejiang Jiaao Environmental Technology Co., which can convert 10,000 barrels of kitchen waste oil daily into SAF, equating to an annual capacity of approximately 500,000 tons [3][29] - Huayi Group's subsidiary was ordered to halt production due to environmental issues, impacting its revenue, which was 779 million yuan with a net loss of 41.24 million yuan for the first nine months of 2025 [3][30][32] - The semiconductor materials sector is experiencing rapid domestic production acceleration, with significant growth in downstream wafer fabrication plants, particularly for photoresist materials and specialty gases [3][28] Market Overview - The Wind New Materials Index closed at 5048.06 points, up 0.66% week-on-week. The semiconductor materials index rose by 6.48% to 7949.5 points, while the display device materials index fell by 3.02% [2][10] - The top five gainers included Guoci Materials (23.46%), Blue Sky Technology (18.13%), and Boqian New Materials (13.69%), while the top five losers included Hongbo New Materials (-11.5%) and Chenguang New Materials (-10.76%) [2][24][26] Recent Industry Highlights - The global semiconductor sales reached $72.7 billion in October, with China experiencing an 18.5% year-on-year growth [28] - Syensqo secured a long-term supply agreement with Vertical Aerospace for high-performance composite materials for their eVTOL aircraft [29] - Huayi Group's subsidiary's production halt is aimed at addressing environmental risks, with efforts to minimize the impact on overall production capacity [30][32] - Huigu New Materials successfully passed its IPO, aiming to expand production capacity by 130,000 tons [33]

证券研究报告|金融工程专题 2025年12月14日 如何用ETF战胜偏股型基金指数 证券分析师： 李杨 执业证书编号：S0210524100005 何佳玮 执业证书编号：S0210524100005 请务必阅读报告末页的重要声明 华福证券 华福证券 投资要点 2 华福证券 华福证券 ➢ 配置宽基ETF复刻偏股型基金指数。配置部分策略目标为复刻偏股型基金指数（930950.CSI），要求基金持仓上 往偏股型基金的持仓和暴露靠近。每月末，用过去N日的宽基ETF跟踪指数日频收益数据对偏股型基金指数回归 得到权重，权重小于5%的指数剔除，剩余指数为基础配置中的指数持仓；对应ETF产品的选择，筛选跟踪同一 指数的ETF中成本更低、流动性更强、跟踪更稳定的1-2只产品，形成宽基ETF池。从2016年1月4日起至2025年 11月28日年化收益7.53%、超额年化3.07%，跟踪误差6.83%。 ➢ 行业主题、策略ETF的分层聚类与优选。基于指数的价格行为，每半年对行业主题、策略指数做聚类划分。按照 聚类划分结果对指数做初步筛选，剔除基本面景气度较差的指数，优选高动量、高夏普、低拥挤度的指数，最后 各指数保留2个ETF产品 ...

Investment Rating - The industry rating is "Outperform the Market" [7][76] Core Insights - The report emphasizes the importance of external demand-driven CXO investment opportunities due to the recent interest rate cuts by the Federal Reserve and the elimination of policy uncertainties related to the new Biosecurity Act [4][29] - The report highlights a mixed performance in the pharmaceutical sector, with a notable focus on innovative drugs and medical devices as key investment areas for the upcoming year [5][34] Summary by Sections Market Review - The CITIC Pharmaceutical Index fell by 1.1% during the week of December 8-12, 2025, underperforming the CSI 300 Index by 1.0 percentage points, ranking 15th among CITIC's primary industry classifications [3][34] - Year-to-date, the CITIC Pharmaceutical Biotech Index has risen by 15.6%, still underperforming the CSI 300 Index by 0.8 percentage points, ranking 16th [3][34] - Top-performing stocks for the week included Zhaoyan New Drug (+23.4%), Hotgen Biotech (+16.8%), and Haichuang Pharmaceutical (+13.9%) [3][53] Investment Opportunities - The Federal Reserve's recent interest rate cut is expected to improve overseas biotech investment and financing conditions, which will benefit CDMO (Contract Development and Manufacturing Organization) orders [4][21] - The new Biosecurity Act, which has passed the House and is awaiting Senate approval, is expected to have a limited impact on external demand for CXO companies, alleviating valuation pressures in the sector [4][28] Sector Performance - The pharmaceutical sector's overall valuation as of December 12, 2025, is 28.79, reflecting a slight decrease of 0.17, with a relative valuation premium of 12.02% compared to the broader market [44] - The total trading volume for the pharmaceutical sector during the week was 423.43 billion, accounting for 4.3% of the total A-share trading volume, with a 3.9% increase from the previous week [50][53]

1. Report Industry Investment Rating - Not provided in the document 2. Core View of the Report - The central economic work conference shows increased confidence in the economy and a shift towards high - quality development. Fiscal and monetary policies will continue the 2024 tone. The 2026 deficit rate may remain at 4%, and government bond supply may only slightly increase. The central bank is cautious about the timing of interest rate cuts, and the implementation of reserve requirement ratio and interest rate cuts may require a change in the policy's perception of the fundamentals. If credit expansion is lower than expected, there may be an adjustment in policy orientation in Q1. The current bond market reaction is less active than in 2023, and the performance of the A - share market is also worthy of further observation. The year - end liquidity is expected to remain loose [4][5][31] 3. Summary by Relevant Catalogs 3.1 1.1 This Week's Fundamentals Review - The central bank's 7 - day reverse repurchase had a net injection of 4.7 billion yuan this week, with limited impact. Due to low initial - month capital demand and reduced government bond payment pressure, funds remained loose. The overnight anonymous lower limit dropped to 1.25%, and DR001 fell below 1.30% after Tuesday and continued to decline, reaching 1.27% on Friday, a new low since August 2023. The central bank will conduct a 600 - billion - yuan 6 - month repurchase operation on the 15th, with a net injection of 200 billion yuan [2][17] - The trading volume of pledged repurchase continued to rise, with the daily average volume increasing by 150 billion yuan to 8.08 trillion yuan compared to last week, reaching a new high since July. Banks' net lending increased compared to last week, with joint - stock banks having the largest increase; non - bank institutions' rigid borrowing scale continued to rise, with funds having the largest increase. The capital gap index fluctuated and declined, reaching - 716.3 billion yuan on Friday, lower than - 470.8 billion yuan last Friday [3][23] 3.2 1.2 Next Week's Fund Outlook - The scale of next week's 7 - day reverse repurchase maturity will slightly increase from 663.8 billion yuan to 668.5 billion yuan. The net payment scale of government bonds will drop from 14.8 billion yuan this week to - 3.9 billion yuan, mainly concentrated in the second half of the week, but the overall scale is relatively limited. On the 15th, the central bank will conduct a 600 - billion - yuan 6 - month repurchase operation, with a net injection of 200 billion yuan. The online issuance of Beijie Stock Exchange's new stock Jiangtian Technology on the 16th may disrupt the exchange's capital prices from Tuesday to Wednesday. The DR001 is expected to remain in the range of 1.3% - 1.4% and may slightly decline, and there may be some fluctuations in the second half of the month, but the year - end liquidity is expected to remain loose [10][68] - The scale of next week's national debt payment is about 304 billion yuan, and the local debt issuance scale of 6 regions is 40 billion yuan, with an actual payment scale of 56.3 billion yuan. The net payment scale of government bonds will drop to - 3.9 billion yuan. It is estimated that the national debt issuance scale in December will be about 1.8 trillion yuan and the net financing scale will be about 320 billion yuan; the local debt issuance scale will be about 350 billion yuan and the net financing scale will be about 230 billion yuan. The overall government bond issuance scale in December is expected to be about 2.15 trillion yuan, and the net financing will be about 54 billion yuan [6][58] 3.3 2. Inter - bank Certificates of Deposit - The 1 - year Shibor rate rose 0.1BP to 1.65% compared to December 5th. The secondary rate of 1 - year AAA - rated inter - bank certificates of deposit rose 0.5BP to 1.66% compared to last week [69] - This week, the increase in the issuance scale of inter - bank certificates of deposit was less than the maturity scale, and they turned to a net repayment of 119.6 billion yuan, a decrease of 128.9 billion yuan compared to last week. The net financing scales of state - owned banks, rural commercial banks, city commercial banks, and joint - stock banks were - 16.2 billion yuan, - 18.3 billion yuan, 3.4 billion yuan, and - 68.5 billion yuan respectively. The issuance proportion of 6 - month certificates of deposit was the highest at 43%, and the issuance proportion of 1 - year certificates of deposit decreased from 22% to 15%. The maturity scale of certificates of deposit next week is about 1.0648 trillion yuan, an increase of 3.4 billion yuan compared to this week [11][74] - The issuance success rates of state - owned banks, joint - stock banks, and city commercial banks increased compared to last week, while that of rural commercial banks decreased, and all banks were near the average level in recent years. The issuance spread of 1 - year certificates of deposit between city commercial banks and joint - stock banks narrowed. The relative supply - demand strength index of certificates of deposit fluctuated upward, mainly due to the significant increase in the willingness of money market funds to increase holdings. The index rose to 33.7% on Friday, an increase of 5.2 percentage points compared to last week. The supply - demand index of 1 - year varieties decreased, while those of other maturities increased [11][86] 3.4 3. Bill Market - Bill rates continued to rise after Wednesday. As of December 12th, the rates of 3 - month and 6 - month national bills rose 3BP and 9BP respectively compared to December 5th, reaching 0.45% and 0.90% [94] 3.5 4. Bond Trading Sentiment Tracking - The bond market fluctuated strongly this week, and the credit and perpetual bond spreads were generally stable. The willingness of large banks to increase bond holdings increased, especially for inter - bank certificates of deposit, short - term national bonds, and short - term policy financial bonds. Trading institutions tended to increase bond holdings, while the willingness of allocation institutions to increase bond holdings decreased significantly [12][96]

Group 1: Theme Identification and Investment Strategies - The report aims to create a tool for theme investment by identifying theme opportunities through comprehensive screening of theme indices, allowing investment managers to focus on logical analysis and decision-making[3] - It emphasizes the construction of investable theme indices by mapping stocks and convertible bonds, providing sector classification and institutional holdings as auxiliary indicators[3] - The "right-side breakout" strategy captures signals for theme initiation, focusing on participating in the first wave of market movements, especially in bullish and volatile markets[4] Group 2: Performance Metrics and Backtesting Results - Backtesting results indicate that the right-side breakout strategy shows significant excess returns, particularly in bullish markets, with a holding period success rate of 69.6% and an average return of 5.1% in 2024[24] - The right-side trend strategy is designed to identify long-term upward trends, with a focus on timing exits, showing significant excess returns in both volatile and bullish markets[42] - The bottom stabilization and reversal strategies are aimed at identifying opportunities at low price levels, with backtesting showing a 50.5% success rate and an average return of 0.9% over five days from 2021 to 2024[51] Group 3: Institutional Participation and Risk Factors - As of Q3 2025, indices with a 2-5% fund holding ratio accounted for the highest proportion at 43.4%, with technology theme indices like optical modules having the highest fund holding at 20.4%[56] - The report highlights several risk factors, including historical performance not guaranteeing future results, industry uncertainties, and geopolitical risks[4]

利率回暖信用债企稳 二永债表现相对强势 —— 信用利差周度跟踪 20251212 投资要点： 华福证券 2025 年 12 月 14 日 ➢ 利率震荡下行信用债企稳，信用利差多数略有走阔。本周利率债总体 震荡偏强，信用债除 7Y 期品种外，收益率多数跟随利率下行。1Y 期 AA 及以上等级信用债收益率下行 1BP，AA-级下行 7BP；3Y 期各等级信用债 收益下行 1-3BP；5Y 期 AAA 级信用债收益率下行 3BP，AA+级持平，AA 级上行 2BP，AA-级下行 1BP；7Y 期各等级信用债收益率上行 1-2BP；10Y 期各等级信用债收益率下行 1BP。信用利差多数略有走阔。 ➢ 本周城投债利差多数上行 1-2BP。外部评级 AA 和 AA+平台信用利差 总体较上周均上行 2BP，AAA 平台总体上行 1BP。分行政级别来看，省级、 地市级和区县级平台信用利差总体较上周均上行 2BP。 ➢ 产业债利差总体上行，混合所有制和民企地产债利差升幅较大。本周 央国企地产债利差上行 3-4BP，混合所有制地产债利差上行 17BP，民企地 产债利差上行 26BP。各等级煤炭债利差上行 1BP；AAA 等级钢铁 ...

Investment Insights - The ongoing competition in computing power chips between China and the US is a significant indicator of long-term global technological deflation [2] - The potential collapse of the US AI bubble could lead to a simultaneous release of global dollar debt risks [2] - Attention should be paid to the risk signals indicated by a potential temporary strengthening of the dollar, which may subsequently lead to a triple hit on the dollar, US bonds, and US stocks [2] - The Chinese market is expected to undergo a long-term style shift during the release of overseas risks, accompanied by a significant and sustained appreciation of the Renminbi [2] Sector and Company Focus - Long-term optimism is noted for sectors such as insurance, central state-owned enterprises, anti-involution industries, Chinese internet companies, and military trade [3] - The recent FOMC meeting indicated a shift to a neutral stance, with the Fed no longer pre-setting a path for interest rate cuts, which will depend on future economic data [8][9] - The Fed acknowledged a cooling labor market, with potential negative employment growth, which explains the decision to cut rates despite inflation remaining above target [9] - The report highlights a complex economic scenario characterized by high growth and weak employment, partly attributed to increased productivity [9] Market Performance - The Hong Kong stock market saw declines, with the Hang Seng Index down by 0.42% and the Hang Seng China Enterprises Index down by 1.29% [13] - In the A-share market, the Shanghai Composite Index fell by 0.34%, while the ChiNext Index rose by 2.74%, indicating a rebound in growth stocks [20] - Sector performance showed a clear divergence, with technology and advanced manufacturing leading gains, while cyclical, consumer, and healthcare sectors experienced declines [27]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [16]. Core Insights - The controlling shareholder and actual controller of the company, Yao Liang Song, has shown confidence by increasing his stake through his spouse, Zhang Qiu Fang, who purchased 210,000 shares for a total of 10.47 million yuan, representing 0.03% of the total share capital [2]. - The company has a robust cash position, with a commitment to distribute at least 1.5 billion yuan in cash dividends annually over the next three years, supported by a net cash balance of 9.4 billion yuan as of June 30, 2025 [3]. - The company's operating profit for the first three quarters of 2025 increased by 3.2% year-on-year, indicating a solid underlying business performance despite challenges in net profit [4]. - The report forecasts net profits for 2025-2027 to be 2.44 billion yuan, 2.67 billion yuan, and 2.91 billion yuan, with growth rates of -6.1%, +9.3%, and +9.0% respectively, suggesting a recovery trend [4]. Financial Data and Valuation - The company is projected to have revenues of 18.31 billion yuan in 2025, with a slight decline from 2024, followed by a recovery to 19.30 billion yuan in 2026 and 20.34 billion yuan in 2027 [6]. - The earnings per share (EPS) is expected to decrease to 4.01 yuan in 2025, before rising to 4.38 yuan in 2026 and 4.77 yuan in 2027 [6]. - The price-to-earnings (P/E) ratio is estimated at 12.6x for 2025, indicating a relatively attractive valuation compared to historical levels [6].

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report emphasizes the positive changes in the Biodefense Act and highlights the investment opportunities in external demand-oriented CXO companies due to the expected improvement in overseas financing and the easing of policy uncertainties [4][26] - The report notes that the recent Federal Reserve interest rate cut is expected to enhance overseas investment in the biotech sector, which will benefit CDMO companies through increased overseas orders [4][21] - The new Biodefense Act is less stringent than previous versions, which is expected to have a limited impact on external demand-oriented CXO companies, potentially lifting valuation pressures on the sector [4][26] Summary by Sections Market Review - During the week of December 8-12, 2025, the CITIC Pharmaceutical Index fell by 1.1%, underperforming the CSI 300 Index by 1.0 percentage points, ranking 15th among CITIC's primary industry classifications [3][32] - Year-to-date, the CITIC Pharmaceutical and Biotech Index has risen by 15.6%, underperforming the CSI 300 Index by 0.8 percentage points, ranking 16th among CITIC's industry classifications [3][32] - The top five performing stocks for the week were: Zhaoyan New Drug (+23.4%), Rejing Biotech (+16.8%), Haichuang Pharmaceutical (+13.9%), Wanze Co. (+13.4%), and Zhongyao Holdings (+13%) [3][49] Investment Opportunities - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as potential big BD targets based on technological and industrial trends [5] - It also highlights opportunities in medical devices, especially in areas like endoscopy and robotics, and emphasizes the importance of innovative consumables supported by national policies [5] - The report indicates a shift towards domestic demand-driven companies as the central economic work conference emphasizes building a strong domestic market [5] Recommendations - The report recommends a focus on the following companies: Kangfang Biotech, WuXi AppTec, Kanglong Huacheng, Baiaosaitu, Bairen Medical, and Kangzhong Medical for December [5][12]

Investment Rating - The industry maintains a rating of "Outperform the Market" [7] Core Views - The report emphasizes that the fundamental goal is to reverse the Producer Price Index (PPI) rather than merely addressing internal competition. Seasonal demand during the "迎峰度冬" period has led to a 4.1% increase in coal mining and washing prices, contributing to a 0.1% month-on-month rise in PPI, marking two consecutive months of increase. The strong correlation between PPI and coal prices suggests that stabilizing coal prices is crucial. The lowest coal price in 2025 may represent a policy bottom, with expectations for more supply-side policies as "involution" competition is addressed in the 14th Five-Year Plan. Despite unclear demand changes, coal prices are expected to fluctuate upward, with a focus on high-quality core assets as primary investment targets [5][6]. Summary by Sections Coal Market Overview - As of December 12, 2025, the Qinhuangdao 5500K thermal coal price is 745 CNY/ton, down 40 CNY/ton week-on-week, with a year-on-year decrease of 49 CNY/ton. The average daily output of 462 sample mines is 5.571 million tons, up 59,000 tons week-on-week but down 5.6% year-on-year. Power plant daily consumption has slightly increased, while coal inventory at Qinhuangdao has surged, with a coal inventory index of 212, up 10.7% [3][5]. Coking Coal - As of December 12, 2025, the price of main coking coal at Jingtang Port is stable at 1,630 CNY/ton. The average daily output of 523 sample mines is 750,000 tons, down 0.4% year-on-year. The daily iron output is 2.291 million tons, down 1.4% year-on-year. The coking plant operating rate is 77.3%, slightly up week-on-week [4][6]. Investment Opportunities - The report suggests focusing on investment opportunities in the coal sector based on several criteria: 1. Companies with excellent resource endowments and stable operating performance, such as China Shenhua, China Coal Energy, and Shaanxi Coal and Chemical Industry. 2. Companies with production growth potential benefiting from the coal price cycle, including Yanzhou Coal Mining, Huayang Co., Guanghui Energy, Jinkong Coal Industry, and Gansu Energy. 3. Companies with globally scarce resources benefiting from long-term supply tightness, such as Huaibei Mining, Pingmei Shenma, Shanxi Coking Coal, Lu'an Environmental Energy, and Shanxi Coal International. 4. Companies with coal-electricity integration models that stabilize cyclical fluctuations, including Shaanxi Energy, Xinji Energy, and Huaihe Energy [6][5].